Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CD8+ T Lymphocytes Immune Depletion and LAG-3 Overexpression in Hodgkin Lymphoma Tumor Microenvironment Exposed to Anti-PD-1 Immunotherapy.
Michot JM, Mouraud S, Adam J, Lazarovici J, Bigenwald C, Rigaud C, Tselikas L, Dartigues P, Danu A, Bigorgne A, Minard V, Ghez D, Marabelle A, Zitvogel L, Ribrag V. Michot JM, et al. Among authors: bigenwald c. Cancers (Basel). 2021 Oct 31;13(21):5487. doi: 10.3390/cancers13215487. Cancers (Basel). 2021. PMID: 34771650 Free PMC article.
Immune-related adverse events with immune checkpoint blockade: a comprehensive review.
Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, Berdelou A, Varga A, Bahleda R, Hollebecque A, Massard C, Fuerea A, Ribrag V, Gazzah A, Armand JP, Amellal N, Angevin E, Noel N, Boutros C, Mateus C, Robert C, Soria JC, Marabelle A, Lambotte O. Michot JM, et al. Among authors: bigenwald c. Eur J Cancer. 2016 Feb;54:139-148. doi: 10.1016/j.ejca.2015.11.016. Epub 2016 Jan 5. Eur J Cancer. 2016. PMID: 26765102 Review.
Outcomes and prognostic factors for relapsed or refractory lymphoma patients in phase I clinical trials.
Michot JM, Benajiba L, Faivre L, Baldini C, Haddag L, Bonnet C, Massard C, Bigot F, Bigenwald C, Verret B, Thomas ZAP, Varga A, Gazzah A, Hollebecque A, Ghez D, Lazarovici J, Balheda R, Jeanson A, Postel-Vinay S, Danu A, Soria JC, Paoletti X, Ribrag V. Michot JM, et al. Among authors: bigenwald c. Invest New Drugs. 2018 Feb;36(1):62-74. doi: 10.1007/s10637-017-0480-x. Epub 2017 Jun 9. Invest New Drugs. 2018. PMID: 28597151 Clinical Trial.
The Polarity and Specificity of Antiviral T Lymphocyte Responses Determine Susceptibility to SARS-CoV-2 Infection in Patients with Cancer and Healthy Individuals.
Fahrner JE, Lahmar I, Goubet AG, Haddad Y, Carrier A, Mazzenga M, Drubay D, Alves Costa Silva C; Lyon COVID Study Group; de Sousa E, Thelemaque C, Melenotte C, Dubuisson A, Geraud A, Ferrere G, Birebent R, Bigenwald C, Picard M, Cerbone L, Lérias JR, Laparra A, Bernard-Tessier A, Kloeckner B, Gazzano M, Danlos FX, Terrisse S, Pizzato E, Flament C, Ly P, Tartour E, Benhamouda N, Meziani L, Ahmed-Belkacem A, Miyara M, Gorochov G, Barlesi F, Trubert A, Ungar B, Estrada Y, Pradon C, Gallois E, Pommeret F, Colomba E, Lavaud P, Deloger M, Droin N, Deutsch E, Gachot B, Spano JP, Merad M, Scotté F, Marabelle A, Griscelli F, Blay JY, Soria JC, Merad M, André F, Villemonteix J, Chevalier MF, Caillat-Zucman S, Fenollar F, Guttman-Yassky E, Launay O, Kroemer G, La Scola B, Maeurer M, Derosa L, Zitvogel L. Fahrner JE, et al. Among authors: bigenwald c. Cancer Discov. 2022 Apr 1;12(4):958-983. doi: 10.1158/2159-8290.CD-21-1441. Cancer Discov. 2022. PMID: 35179201 Free PMC article.
Clinical significance of the loss of CD20 antigen on tumor cells in patients with relapsed or refractory follicular lymphoma.
Michot JM, Buet-Elfassy A, Annereau M, Lazarovici J, Danu A, Sarkozy C, Chahine C, Bigenwald C, Bosq J, Rossignol J, Romano-Martin P, Baldini C, Ghez D, Dartigues P, Massard C, Ribrag V. Michot JM, et al. Among authors: bigenwald c. Cancer Drug Resist. 2021 Mar 26;4(3):710-718. doi: 10.20517/cdr.2020.109. eCollection 2021. Cancer Drug Resist. 2021. PMID: 35582306 Free PMC article.
Sequence analyses of relapsed or refractory diffuse large B-cell lymphomas unravel three genetic subgroups of patients and the GNA13 mutant as poor prognostic biomarker, results of LNH-EP1 study.
Michot JM, Quivoron C, Sarkozy C, Danu A, Lazarovici J, Saleh K, El-Dakdouki Y, Goldschmidt V, Bigenwald C, Dragani M, Bahleda R, Baldini C, Arfi-Rouche J, Martin-Romano P, Tselikas L, Gazzah A, Hollebecque A, Lacroix L, Ghez D, Vergé V, Marzac C, Cotteret S, Rahali W, Soria JC, Massard C, Bernard OA, Dartigues P, Camara-Clayette V, Ribrag V. Michot JM, et al. Among authors: bigenwald c. Am J Hematol. 2023 Apr;98(4):645-657. doi: 10.1002/ajh.26835. Epub 2023 Jan 18. Am J Hematol. 2023. PMID: 36606708 Free article.
RBD- specific Th1 responses are associated with vaccine-induced protection against SARS-CoV-2 infection in patients with hematological malignancies.
Bigenwald C, Haddad Y, Thelemaque C, Carrier A, Birebent R, Ly P, Flament C, Lahmar I, de Sousa E, Maeurer M, Miyara M, Assi T, Castilla-Llorente C, Willekens C, Fayemi C, Lazarovici J, Marabelle A, Derosa L, Ribrag V, Zitvogel L. Bigenwald C, et al. Oncoimmunology. 2023 Jan 4;12(1):2163785. doi: 10.1080/2162402X.2022.2163785. eCollection 2023. Oncoimmunology. 2023. PMID: 36632566 Free PMC article.
Light shed from the gut in large B-cell lymphoma.
Bigenwald C, Zitvogel L. Bigenwald C, et al. Blood. 2023 May 4;141(18):2165-2166. doi: 10.1182/blood.2023019858. Blood. 2023. PMID: 37140955 Free article. No abstract available.
26 results